AMPH Q3 2024 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$189M+4.6% YoY

Gross Profit

$102M54.0% margin

Operating Income

$57M30.2% margin

Net Income

$40M21.4% margin

EPS (Diluted)

$0.78

QoQ Revenue Growth

+3.5%

Cash Flow

Operating Cash Flow

$60M

Free Cash Flow

$46M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$818M

Stockholders' Equity

$728M

Cash & Equivalents

$192M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$189M	$181M	+4.6%
Gross Profit	$102M	$108M	-6.0%
Operating Income	$57M	$73M	-21.5%
Net Income	$40M	$49M	-17.9%

Revenue Segments

Product

$189M99%

Product and Service, Other

$2M1%

Geographic Segments

UNITED STATES

$187M98%

FRANCE

$5M2%

CHINA

$178,0000%